The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia
Open accessAbstract
OBJECTIVE: Tardive dyskinesia is a persistent movement disorder induced by dopamine receptor blockers, including antipsychotics. Valbenazine (NBI-98854) is a novel, highly selective vesicular monoamine transporter 2 inhibitor that demonstrated favorable efficacy and tolerability in the treatment of tardive dyskinesia in phase 2 studies. This phase 3 study further evaluated the efficacy, safety, and tolerability of valbenazine as a treatment for tardive dyskinesia. METHOD: This 6-week, randomized, double-blind, placebo-controlled trial included patients with schizophrenia, schizoaffective disorder, or a mood disorder who had moderate or severe tardive dyskinesia. Participants were randomly assigned in a 1:1:1 ratio to once-daily placebo, valbenazine at 40 mg/day, or valbenazine at 80 mg/day. The primary efficacy endpoint was change from baseline to week 6 in the 80 mg/day group compared with the placebo group on the Abnormal Involuntary Movement Scale (AIMS) dyskinesia score (items 1-7), as assessed by blinded central AIMS video raters. Safety assessments included adverse event monitoring, laboratory tests, ECG, and psychiatric measures. RESULTS: The intent-to-treat population included 225 participants, of whom 205 completed the study. Approximately 65% of participants had schizophrenia or schizoaffective disorder, and 85.5% were receiving concomitant antipsychotics. Least squares mean change from baseline to week 6 in AIMS dyskinesia score was -3.2 for the 80 mg/day group, compared with -0.1 for the placebo group, a significant difference. AIMS dyskinesia score was also reduced in the 40 mg/day group (-1.9 compared with -0.1). The incidence of adverse events was consistent with previous studies. CONCLUSIONS: Once-daily valbenazine significantly improved tardive dyskinesia in participants with underlying schizophrenia, schizoaffective disorder, or mood disorder. Valbenazine was generally well tolerated, and psychiatric status remained stable. Longer trials are necessary to understand the long-term effects of valbenazine in patients with tardive dyskinesia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
A New Brief Instrument for Assessing Decisional Capacity for Clinical Research
Jeste, D. V., Palmer, B. W., Appelbaum, P. S., Golshan, S., Glorioso, D., Dunn, L. B., Kim, K., Meeks, T., & Kraemer, H. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.8.966 · Cited by 586
Long-term effects of tetrabenazine in hyperkinetic movement disorders
Jankovic, J., & Beach, J. (1997) · Neurology · doi:10.1212/wnl.48.2.358 · Cited by 352
Bhidayasiri, R., Fahn, S., Weiner, W. J., Gronseth, G. S., Sullivan, K. L., & Zesiewicz, T. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31829d86b6 · Cited by 211
An Update on Tardive Dyskinesia: From Phenomenology to Treatment
Waln, O., & Jankovic, J. J. (2013) · PubMed · doi:10.7916/d88p5z71 · Cited by 198
Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.
Caroff, S. N., Hurford, I., Lybrand, J., & Campbell, E. C. (2011) · Neurologic Clinics · doi:10.1016/j.ncl.2010.10.002 · Cited by 188
Woods, S. W., Morgenstern, H., Saksa, J. R., Walsh, B. C., Sullivan, M. C., Money, R., Hawkins, K. A., Gueorguieva, R. V., & Glazer, W. M. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03890yel · Cited by 186
Compelling or irrelevant? Using number needed to treat can help decide
Citrome, L. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01194.x · Cited by 158
Dopamine depleters in the treatment of hyperkinetic movement disorders
Jankovic, J. J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1258063 · Cited by 144
O’Brien, C. F., Jimenez, R., Hauser, R. A., Factor, S. A., Burke, J., Mandri, D., & Castro‐Gayol, J. C. (2015) · Movement Disorders · doi:10.1002/mds.26330 · Cited by 133
Self-citationTardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder
Cloud, L. J., Zutshi, D., & Factor, S. A. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0222-5 · Cited by 125
Self-citationExtract of Ginkgo biloba Treatment for Tardive Dyskinesia in Schizophrenia
Zhang, W.-F., Tan, Y.-L., Zhang, X., Chan, R. C. K., Wu, H.-R., & Zhou, D.-F. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05125yel · Cited by 98
Zutshi, D., Cloud, L. J., & Factor, S. A. (2014) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.199 · Cited by 71
Self-citationZutshi, D., Factor, S., & Cloud, L. J. (2014) · PubMed Central · doi:10.7916/d85h7dzx · Cited by 67
Self-citationNew and emerging treatments for symptomatic tardive dyskinesia
Rana, A. Q., Chaudry, Z. M., & Blanchet, P. J. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s32328 · Cited by 63
Valbenazine granted breakthrough drug status for treating tardive dyskinesia
Müller, T. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1029573 · Cited by 55
Subjective awareness of tardive dyskinesia and insight in schizophrenia
Emsley, R. A., Niehaus, D. J. H., Oosthuizen, P., Koen, L., Chiliza, B., & Fincham, D. S. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2009.12.006 · Cited by 30
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Management of common adverse effects of antipsychotic medications
Stroup, T. S., & Gray, N. (2018) · World Psychiatry · doi:10.1002/wps.20567 · Cited by 572
Anderson, K. E., Stamler, D., Davis, M. D., Factor, S. A., Hauser, R. A., Isojärvi, J., Jarskog, L. F., Jimenez-Shahed, J., Kumar, R., McEvoy, J. P., et al. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30236-5 · Cited by 337
Self-citationSolmi, M., Pigato, G., Kane, J. M., & Correll, C. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s133205 · Cited by 88
Metoclopramide for the treatment of diabetic gastroparesis
Shakhatreh, M., Jehangir, A., Malik, Z., & Parkman, H. P. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1645594 · Cited by 83
Metadata
- Authors
- Hauser, R. A., Factor, S. A., Marder, S. R., Knesevich, M. A., Ramirez, P. M., Jimenez, R., Burke, J., Liang, G. S., & O’Brien, C. F.
- Venue
- American Journal of Psychiatry
- Published
- 2017-05-01
- Volume
- 174
- Issue
- 5
- Pages
- 476-484
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2598837636
- Cited by
- 392
- References
- 23
- FWCI
- 56.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.